NEW YORK (TheStreet) -- RATINGS CHANGES
Abercrombie & Fitch (ANF) was upgraded to buy at TheStreet Ratings.
Anadarko (APC) was upgraded to overweight at J.P. Morgan. The company has settled its Tronox lawsuit, J.P. Morgan said.
Dynergy (DYN) was upgraded to neutral from sell at UBS. $25 12-month price target. The change was driven by expectations that the company will be allowed to bid in PJM MAAC pricing in the upcoming MISO capacity auction, said UBS.
Genesco (GCO) was upgraded to buy at Sterne Agee. $85 12-month price target. The company is seeing higher growth at Lids, Sterne Agee said.
Gamestop (GME) was upgraded to buy from neutral at Bank of America/Merrill Lynch. $56 12-month price target. The company appears to be at an inflection point, BofA/Merrill said.
Huntsman (HUN) was upgraded to buy from neutral at UBS. $32 12-month price target. There is greater confidence in accretion from TiO2 deal and improving portfolio mix and consistency, said UBS.
McClatchy (MNI) was upgraded to hold at TheStreet Ratings.
Scripps (SNI) was upgraded to buy from hold at Wunderlich. $90 12-month price target. This was a valuation call, as the stock is down 12% year-to-date, Scripps said..
Stock Comments / EPS Changes
Archer-Daniels-Midland (ADM) numbers were boosted at Citi. Shares are now seen reaching a 12-month price target of $50, according to Citigroup. Estimates were also upped, given higher expected growth in corn processing and oilseeds, Citigroup said. Buy rating.
Walt Disney (DIS) numbers were raised at Bank of America/Merrill Lynch. Shares are now seen reaching $94, according to BofA/Merrill. Estimates were also increased, as Frozen continues to drive studio growth, BofA/Merrill said. Buy rating.
Micron (MU) price target was upped at Jefferies. Micron raised its number, Jefferies said. DRAM gross margins increase by 4,00 bps to drive profitability, said Jeffries. $32 12-month price target and buy rating.
Mylan (MYL) estimates, price target were cut at Leerink Swann. Shares are now seen reaching $58, according to Leerink. Estimates were also reduced, given prescription trends and new product delays, Leerink said. Outperform rating.